Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NEUROCRINE BIOSCIENCES INC

Get SEC filing alerts via email and in your feed for NEUROCRINE BIOSCIENCES INC

NBIX

NEUROCRINE BIOSCIENCES INC

About NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences is a biopharmaceutical company specializing in neuroscience. It develops and commercializes treatments for neuropsychiatric, neurological, and neuroendocrine disorders, including FDA-approved drugs like INGREZZA for tardive dyskinesia and Huntington's chorea, and CRENESSITY for congenital adrenal hyperplasia. The company focuses on innovative pipelines across small molecules, peptides, proteins, antibodies, and gene therapies, serving global markets with a competitive edge in rare and underserved neurological conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NEUROCRINE BIOSCIENCES INC

1
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports 42.3% Revenue Growth to $814.5 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports 21.6% Revenue Growth to $2.86 Billion in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports 28% Revenue Growth to $794.9 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports 16.5% Revenue Growth to $687.5 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports 11% Revenue Growth but Declines in Net Income for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports $2.33 Billion in Net Product Sales for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences Reports Significant Financial Growth and Pipeline Advancements in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments